The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study

Abstract Background Disitamab vedotin (DV, RC48-ADC) has shown promising efficacy and manageable safety as monotherapy or combined with immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) patients progressing after systemic chemotherapy. This study evaluates the efficacy and...

詳細記述

書誌詳細

主要な著者:	Cheoklong Ng, Taile Jing, Shicheng Yu, Jianjun Ye, Shun Zhang, Zhankui Jia, Qi Tang, Xiaoyi Hu, Minfeng Chen, Weiping Huang, Jitao Wu, Hai Bi, Zejun Yan, Haibo Shen, Wei Xiong, Zheng Liu, Jun Xiao, Tao Zhang, Xuedong Wei, Hailong Hu, Qing Yang, Yichu Yuan, Zhiyang Huang, Wei Xue, Yige Bao, Guoqing Ding, Dan Xia, Jiwei Huang
フォーマット:	Artigo
言語:	Inglês
出版事項:	Springer 2025-09-01
シリーズ:	Cancer Immunology, Immunotherapy
主題:	Disitamab vedotin Immune checkpoint inhibitors Upper tract urothelial carcinoma Targeted therapy Immunotherapy
オンライン･アクセス:	https://doi.org/10.1007/s00262-025-04154-5
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!